• KOL
    • Hyperactivity Disorder
    • Thomas J Spencer
    • Thomas J Spencer: Influence Statistics

      Thomas J Spencer

      Thomas J Spencer

      Show email address

      Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, Massachusetts, USA. | Home Base: A Red Sox Foundation ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Thomas J Spencer:Expert Impact

      Concepts for whichThomas J Spencerhas direct influence:Hyperactivity disorder,Attention deficit,Adults adhd,Deficit hyperactivity,Bipolar disorder,Adult adhd,Adhd adults,Disorder hyperactivity.

      Thomas J Spencer:KOL impact

      Concepts related to the work of other authors for whichfor which Thomas J Spencer has influence:Hyperactivity disorder,Attention deficit,Adhd symptoms,Children adolescents,Tourette syndrome,College students,Mental health.

      KOL Resume for Thomas J Spencer

      Year
      2020

      Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, Massachusetts, USA.

      Department of Psychiatry.

      Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA

      2019

      Massachusetts General Hospital, Boston, USA

      2018

      Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, Massachusetts, USA.

      Massachusetts General Hospital, 55 Fruit St, Warren 705, Boston, MA 02144.

      2017

      Pediatric Psychopharmacology and Adult ADHD Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA

      Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston

      2016

      Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

      2015

      Department of Psychiatry, Massachusetts General Hospital, MA 02114, USA

      2014

      Clinical and Research Programs in Pediatric Psychopharmacology and ADHD, Massachusetts General Hospital, Boston, MA, USA

      Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114

      2013

      Department of Psychiatry, Pediatric Psychopharmacology Unit, Psychiatry Service, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

      Massachusetts General Hospital, Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, 55 Fruit St-WRN 705, Boston, MA 02114

      2012

      Division of Neuroscience, New England Primate Research Center, Boston, Massachusetts

      Department of Psychiatry, Harvard Medical School, New York, New York.

      2011

      Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Warren, Boston, MA, USA

      Department of Psychiatry, Harvard Medical School, Assistant Chief of Pediatric Psychopharmacology Research Program, Massachusetts General Hospital, Boston, MA

      2010

      Department of Psychiatry, Harvard Medical School, Department of Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA

      Neuroimaging Program, Clinical and Research Programs in Pediatric Psychopharmacology and Adult Attention-Deficit/Hyperactivity Disorder, Massachusetts General Hospital, Boston, Massachusetts

      2009

      Clinical and Research Program, Pediatric Psychopharmacology, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.

      From the *NYU School of Medicine; †New York VA Harbor Healthcare System, New York, NY; ‡Massachusetts General Hospital, Boston, MA; §Yale University School of Medicine, Hamden, CT; ∥Harcourt Assessment, Inc, Bear, DE; ¶NeuroScience, Inc, Herndon, VA; #Lilly Research Laboratories, Indianapolis, IN; **University of Mississippi Medical School, Jackson, MS; ††Indiana University Medical School, Indianapolis, IN; and ‡‡Tufts University School of Medicine, Boston, MA.

      Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA

      State University of New York, Upstate Medical University, Harvard Medical School, Massachusetts General Hospital

      2008

      Stanley Cobb Professor of Psychiatry, Harvard Medical School

      Chief, Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, Massachusetts

      Chair, Partners Psychiatry and Mental Health

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Thomas J Spencer is among the top experts in the world.
      Concept World rank
      tanner stage atomoxetine #1
      adhd extended #1
      literature tourettes disorder #1
      subjects oros mph #1
      randomized adults #1
      mph gxr #1
      maximum shortfall #1
      stage sexual #1
      atomoxetine treatment children #1
      childhood onset adhd #1
      placebo adult adhd #1
      randomized atomoxetine #1
      irmph #1
      stimulants effective #1
      altropane ligand #1
      xr adolescents #1
      placebo oros methylphenidate #1
      robust doses #1
      adhd symptoms placebo #1
      adults illness treatment #1
      placebo tanner stage #1
      adhd primary aim #1
      hyperactivity diagnostic #1
      discontinuation atomoxetine #1
      treatment hyperactivity australia #1
      development atomoxetine #1
      adult adhd response #1
      groups atx #1
      dose oros #1
      comorbid tourette syndrome #1
      relationship dat1 #1
      subjects oros #1
      bupropionsr adhd #1
      illness atx #1
      male propylamines severity #1
      aes dasotraline #1
      atomoxetine pregnancy #1
      longacting mph #1
      doses oros #1
      formulations mph #1
      atomoxetine tic symptoms #1
      oros methylphenidate visit #1
      health adhd #1
      atomoxetine treatment adhd #1
      c11 altropane #1
      discontinuation syndrome recurrence #1
      adhd severity illness #1
      adhd genetic disorder #1
      oncedaily atomoxetine efficacy #1
      60mg xr #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Thomas J Spencer

      KOL-Index: 23285

      BACKGROUND: The ability to recognize and diagnose attention-deficit/hyperactivity disorder (ADHD) has increased in recent years. The persistence of ADHD symptoms puts adolescents with ADHD at risk for long-term adverse psychosocial outcomes.

      OBJECTIVE: The primary goal of this study was to assess the efficacy and safety of mixed amphetamine salts extended release (MAS XR) in the management of adolescents with ADHD.

      METHODS: This was a 4-week, randomized, multicenter, double-blind, ...

      Known for Adolescents Adhd | Mixed Amphetamine Salts | Hyperactivity Disorder | Adderall Xr | Extended Release
      KOL-Index: 16931

      OBJECTIVE: To assess the efficacy and safety of OROS methylphenidate (Concerta; McNeil Pediatrics Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, Titusville, NJ) in the management of attention-deficit/hyperactivity disorder (ADHD) in adults.

      METHODS: A randomized, 7-week, double-blind, placebo-controlled, dose-escalation, parallel-group study of OROS methylphenidate 36, 54, 72, 90, or 108 mg/d versus placebo was conducted in adults with ADHD. The primary end point was the Adult ...

      Known for Oros Methylphenidate | Hyperactivity Disorder | Adults Adhd | Efficacy Safety | Baseline Visit
      KOL-Index: 15469

      OBJECTIVE: Atomoxetine is an investigational, nonstimulant pharmacotherapy being studied as potential treatment for attention-deficit/hyperactivity disorder (ADHD). It is thought to act via blockade of the presynaptic norepinephrine transporter in the brain. We assessed the efficacy of 3 doses of atomoxetine compared with placebo in children and adolescents with ADHD.

      METHODS: A total of 297 children and adolescents who were 8 to 18 years of age and had ADHD as defined by the Diagnostic ...

      Known for Placebo Atomoxetine | Adhd Symptoms | 18 Day | Children Adolescents | Hyperactivity Disorder
      KOL-Index: 15092

      OBJECTIVE: To examine (1) moderating effects of oppositional defiant disorder (ODD) on attention-deficit/hyperactivity disorder (ADHD) treatment response and (2) responses of ODD symptoms to atomoxetine.

      METHOD: Children and adolescents (ages 8-18) with ADHD were treated for approximately 8 weeks with placebo or atomoxetine (fixed dosing: 0.5, 1.2, or 1.8 mg/kg/day, b.i.d.) under randomized, double-blind conditions. Among patients with lifetime diagnostic information (n = 293), 39% were ...

      Known for Atomoxetine Treatment | Adhd Odd | Hyperactivity Disorder | Children Adolescents | Oppositional Defiant
      KOL-Index: 15011

      BACKGROUND: Oppositional defiant disorder (ODD)is associated with a high degree of impairment in social skills, family interaction, and academic functioning. Comorbid ODD is reportedly present in 40% to 70% of children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

      OBJECTIVE: The goal of this study was to assess the efficacy and safety of mixed amphetamine salts extended release (MAS XR) for the treatment of ODD in children and adolescents aged 6 to 17 ...

      Known for Oppositional Defiant Disorder | Mixed Amphetamine Salts | Extended Release | Children Adolescents | Efficacy Safety
      KOL-Index: 15005

      OBJECTIVE: To complete an exploratory uncontrolled study of the effects of lisdexamfetamine dimesylate (LDX) on growth of children treated for attention-deficit/hyperactivity disorder (ADHD).

      METHOD: Height, weight, and body mass index (BMI) from 281 children ages 6 to 13 years from longitudinal assessments up to 15 months were compared to norms from the Centers for Disease Control.

      RESULTS: At study entry, children were taller and heavier than average. Growth delays were largest for ...

      Known for Lisdexamfetamine Dimesylate | Height Weight | Growth Children | Ldx Bmi | Centers Disease Control
      KOL-Index: 14943

      BACKGROUND: Despite the increasing recognition of comorbid attention-deficit/hyperactivity disorder (ADHD) and bipolar disorder (BPD) in adults, there are no prospective trials of pharmacological agents to treat ADHD in these patients. Given the efficacy of bupropion for ADHD in adults, as well as its use in the management of bipolar depression, we studied the tolerability and efficacy of sustained-release (SR) bupropion in adults with ADHD plus BPD.

      METHODS: This was an open, ...

      Known for Bipolar Disorder | Adults Adhd | Treatment Bupropion | Deficit Hyperactivity | Antidepressive Agents
      KOL-Index: 14844

      OBJECTIVE: The aim of this study was to evaluate the safety and effectiveness of guanfacine extended release (GXR) administered concomitantly with psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) and suboptimal response to a psychostimulant alone.

      DESIGN AND METHODS: This was a multicenter, open-label, 9-week, dose-escalation study of 75 subjects with ADHD treated with methylphenidate (MPH) or amphetamine (AMP) alone for at least 1 month, ...

      Known for Guanfacine Extended Release | Hyperactivity Disorder | Children Adolescents | Gxr Mph | Suboptimal Response Psychostimulant
      KOL-Index: 14005

      We examined 140 probands with attention deficit hyperactivity disorder, 120 normal controls, and their 822 first-degree relatives using "blind" raters and structured diagnostic interviews. Compared with controls, probands with attention deficit hyperactivity disorder were more likely to have conduct, mood, and anxiety disorders. Compared with relatives of controls, relatives of probands with attention deficit hyperactivity disorder had a higher risk for attention deficit hyperactivity ...

      Known for Attention Deficit | Hyperactivity Disorder | Referred Samples | Relatives Probands | Patterns Comorbidity
      KOL-Index: 13819

      OBJECTIVE: Diagnosing attention deficit hyperactivity disorder (ADHD) in adults is difficult when diagnosticians cannot establish an onset before the DSM-IV criterion of age 7 or if the number of symptoms recalled does not achieve DSM's diagnosis threshold.

      METHOD: The authors addressed the validity of DSM-IV's age-at-onset and symptom threshold criteria by comparing four groups of adults: 127 subjects with full ADHD who met all DSM-IV criteria for childhood-onset ADHD, 79 subjects with ...

      Known for Late Onset | Deficit Hyperactivity | Adult Attention | Adhd Subjects | Familial Transmission
      KOL-Index: 13305

      BACKGROUND: A self-report screening scale of adult attention-deficit/hyperactivity disorder (ADHD), the World Health Organization (WHO) Adult ADHD Self-Report Scale (ASRS) was developed in conjunction with revision of the WHO Composite International Diagnostic Interview (CIDI). The current report presents data on concordance of the ASRS and of a short-form ASRS screener with blind clinical diagnoses in a community sample.

      METHOD: The ASRS includes 18 questions about frequency of recent ...

      Known for Health Organization | Adult Adhd | Report Scale | Asrs Screener | 18 Questions

      Key People For Hyperactivity Disorder

      Top KOLs in the world
      #1
      JOSEPH Biederman
      bipolar disorder attention deficit adults adhd
      #2
      Stephen V Faraone∗
      hyperactivity disorder attention deficit children adhd
      #3
      Thomas J Spencer
      hyperactivity disorder attention deficit adults adhd
      #4
      Russell A Barkley
      hyperactivity disorder attention deficit hyperactive children
      #5
      James M Swanson
      hyperactivity disorder children adhd attention deficit
      #6
      Jan K Buitelaar∗
      hyperactivity disorder attention deficit adhd symptoms

      Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, Massachusetts, USA. | Home Base: A Red Sox Foundation and Massachusetts General Hospital Program, Massachusetts General Hospital, C

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.